Race, rituximab, and relapse in TTP

Author:

Chaturvedi Shruti1,Antun Ana G.2,Farland Andrew M.3,Woods Ryan3,Metjian Ara4ORCID,Park Yara A.5,de Ridder Gustaaf56,Gibson Briana57,Kasthuri Raj S.8ORCID,Liles Darla K.9,Akwaa Frank10,Clover Todd11,Baumann Kreuziger Lisa1213ORCID,Sadler J. Evan14,Sridharan Meera15ORCID,Go Ronald S.15,McCrae Keith R.16ORCID,Upreti Harsh Vardhan117,Liu Angela1,Lim Ming Y.18ORCID,Gangaraju Radhika19,Zheng X. Long20ORCID,Raval Jay S.21ORCID,Masias Camila22,Cataland Spero R.23,Johnson Andrew24,Davis Elizabeth25,Evans Michael D.26ORCID,Mazepa Marshall A.25ORCID,

Affiliation:

1. 1Department of Medicine, Johns Hopkins University, Baltimore, MD;

2. 2Department of Medicine, Emory University, Atlanta, GA;

3. 3Department of Medicine, Wake Forest University, Winston-Salem, NC;

4. 4Department of Medicine, University of Colorado, Denver, CO;

5. 5Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC;

6. 6Geisinger Medical Laboratories, Danville, PA;

7. 7Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA;

8. 8Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC;

9. 9Department of Medicine, East Carolina University, Greenville, NC;

10. 10Department of Medicine, University of Rochester, Rochester, NY;

11. 11St Charles Healthcare, Bend, OR;

12. 12Versiti Blood Research Institute, Milwaukee, WI;

13. 13Department of Medicine, Medical College of Wisconsin, Milwaukee, WI;

14. 14Department of Medicine, Washington University, St Louis, MO;

15. 15Department of Medicine, Mayo Clinic, Rochester, MN;

16. 16Department of Medicine, Cleveland Clinic, Cleveland, OH;

17. 17Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA;

18. 18Department of Medicine, University of Utah, Salt Lake City, UT;

19. 19Department of Medicine, University of Alabama at Birmingham;

20. 20Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS;

21. 21Department of Pathology, University of New Mexico, Albuquerque, NM;

22. 22Baptist Health South Florida, Miami, FL;

23. 23Department of Medicine, The Ohio State University, Columbus, OH;

24. 24Department of Laboratory Medicine and Pathology and

25. 25Department of Medicine, University of Minnesota, Minneapolis, MN; and

26. 26Clinical & Translational Science Institute, University of Minnesota, Minneapolis, MN

Abstract

Abstract Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by recurring episodes of thrombotic microangiopathy, causing ischemic organ impairment. Black patients are overrepresented in iTTP cohorts in the United States, but racial disparities in iTTP outcome and response to therapy have not been studied. Using the United States Thrombotic Microangiopathies Consortium iTTP Registry, we evaluated the impact of race on mortality and relapse-free survival (RFS) in confirmed iTTP in the United States from 1995 to 2020. We separately examined the impact of rituximab therapy and presentation with newly diagnosed (de novo) or relapsed iTTP on RFS by race. A total of 645 participants with 1308 iTTP episodes were available for analysis. Acute iTTP mortality did not differ by race. When all episodes of iTTP were included, Black race was associated with shorter RFS (hazard ratio [HR], 1.60; 95% CI, 1.16-2.21); the addition of rituximab to corticosteroids improved RFS in White (HR, 0.37; 95% CI, 0.18-0.73) but not Black patients (HR, 0.96; 95% CI, 0.71-1.31). In de novo iTTP, rituximab delayed relapse, but Black patients had shorter RFS than White patients, regardless of treatment. In relapsed iTTP, rituximab significantly improved RFS in White but not Black patients. Race affects overall relapse risk and response to rituximab in iTTP. Black patients may require closer monitoring, earlier retreatment, and alternative immunosuppression after rituximab treatment. How race, racism, and social determinants of health contribute to the disparity in relapse risk in iTTP deserves further study.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3